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With an incidence of *1:3,500 to 5,000 in male children, Duchenne muscular dystrophy (DMD) is an X-linked
disorder in which progressive muscle degeneration occurs and affected boys usually die in their twenties or
thirties. Cardiac involvement occurs in 90% of patients and heart failure accounts for up to 40% of deaths. To
enable new therapeutics such as gene therapy and exon skipping to be tested in human cardiomyocytes, we
produced human induced pluripotent stem cells (hiPSC) from seven patients harboring mutations across the
DMD gene. Mutations were retained during differentiation and analysis indicated the cardiomyocytes showed a
dystrophic gene expression profile. Antisense oligonucleotide-mediated skipping of exon 51 restored dystrophin
expression to *30% of normal levels in hiPSC-cardiomyocytes carrying exon 47–50 or 48–50 deletions. Alter-
natively, delivery of a dystrophin minigene to cardiomyocytes with a deletion in exon 35 or a point mutation in
exon 70 allowed expression levels similar to those seen in healthy cells. This demonstrates that DMD hiPSC-
cardiomyocytes provide a novel tool to evaluate whether new therapeutics can restore dystrophin expression in
the heart.
Introduction
Duchenne muscular dystrophy (DMD) is the mostcommon and most severe inherited neuromuscular dis-
order. Patients present with walking difficulties by 3–6 years
of age and are wheelchair bound by their early teens [1,2].
Clinical management includes high-dose corticosteroids and
nocturnal ventilation [3]. ACE inhibitors and b-blockers can
provide benefit for cardiomyopathy associated with DMD.
These treatments can extend life to the second or third de-
cades. However, steroids often lead to side effects including
weight gain, stunted growth, bone loss, diabetes, cataracts,
and high blood pressure [3]. This has promoted development
of alternative treatments such as exon skipping and gene
therapy [4,5], with both strategies being tested in clinical tri-
als. Exon skipping employs antisense oligonucleotides
(AONs) to hide splice sites, branch points, or exon-internal
sequences from splicing machinery, causing the skipping of
targeted exons [6]. This can restore the reading frame of out of
frame mutations that affect the rod domain of dystrophin, a
region that has a high redundancy of spectrin repeats [6]. The
result is a truncated protein similar to that found in Becker
muscular dystrophy (BMD) patients, who can have an am-
bulant life and can live into their seventies. The most ad-
vanced trials (Phase III, in progress) have used skipping of
exon 51 (http://clinicaltrials.gov/ct2/show/NCT01254019
see [7,8]), which could be effective in 13% of all DMD boys on
account of restoring reading frame in multiple deletions (e.g.,
D exons 45–50, 46–50, 47–50, 48–50, 49–50, 50, 52, 52–63) [9].
In some instances, skipping does not produce a func-
tional truncated protein. This is true when mutations lie in
nonredundant regions of dystrophin, such as the N-terminal
actin-binding domain or the C-terminal b-dystroglycan/
syntrophin binding region. In such cases, early phase I/II
clinical trials have been initiated to test efficacy of delivery of
dystrophin minigenes to dystrophic muscle.
The focus of clinical trials has been primarily on evaluat-
ing the effect of treatments on skeletal muscle [7,8]. How-
ever, with over a third of DMD patients dying of heart
failure, there is an urgent need for methods that evaluate
whether therapeutics can rescue dystrophin expression in
cardiomyocytes. Notably, the impact of skeletal muscle
treatment on cardiac disease in DMD patients is under de-
bate, with some authors suggesting benefit to the heart and
1Wolfson Centre for Stem Cells, Tissue Engineering and Modelling (STEM), Centre for Biomolecular Sciences, University of Nottingham,
Nottingham, United Kingdom.
2Institute of Genetic Medicine, Newcastle University, Centre for Life, Newcastle Upon Tyne, United Kingdom.
3Muscle Immunoanalysis Unit, Dental Hospital, Newcastle Upon Tyne, United Kingdom.
4DMD Genetic Therapy Group, Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
STEM CELLS AND DEVELOPMENT
Volume 22, Number 20, 2013
 Mary Ann Liebert, Inc.
DOI: 10.1089/scd.2013.0135
2714
others detriment [10]. In the latter case, it may be anticipated
that improvements in assisted ventilation will correspond to
an increasing number of patients dying due to heart failure
in the future.
The skeletal muscle clinical trials have benefitted from nu-
merous background studies in which therapeutics have been
tested in cultured muscle cells derived from DMD patients [11].
Such in vitro work has allowed the efficacy of molecular
treatments on human mutations and the patient’s own cells to
be determined [12]. However, there is no parallel in vitro sys-
tem for human cardiomyocytes because primary human car-
diomyocytes do not divide in culture and experiments cannot
be carried out repeatedly on identical cultures. Moreover, pri-
mary human cardiomyocytes are obtained through invasive
procedures (e.g., heart biopsies), thereby potentially putting
patients at risk. An in vitro system that parallels that available
for skeletal muscle would be beneficial, especially since there
are considerable differences between skeletal and cardiac
muscle, including physiology, drug-induced toxicity, and dys-
trophin expression and localization. Moreover, the two tissues
differ in RNA production rate, mRNA levels and mRNA
turnover. Half-life of skipping drugs is longer in the heart but
delivery to cardiomyocytes is less efficient that skeletal muscle
cells. This is because the membrane of DMD skeletal muscle is
more leaky than cardiomyocytes, thereby allowing better up-
take of skipping drugs [13]. Dystrophin levels are higher in the
heart relative to skeletal muscle (Aartsma-Rus, submitted).
These issues could alter the ability to restore dystrophin ex-
pression in the heart. Therefore, access to human cardiomyo-
cytes with various DMDmutations would accelerate preclinical
development of therapeutics.
In this article, we have used epigenetic reprogramming to
produce human induced pluripotent stem cells (hiPSCs)
from skin fibroblasts derived from seven DMD patients who
harbor frame-shifting deletions or nonsense point mutations
in different regions of the DMD gene (5¢ end, middle or 3¢
end). The pluripotent cells were induced to differentiate into
electrophysiologically- and pharmacologically-functional
cardiomyocytes that displayed a dystrophic gene expression
profile. Delivery of AONs directed to exon 51 of the DMD
gene induced exon skipping in DMD hiPSC-cardiomyocytes,
leading to expression of truncated RNA transcripts that
produced dystrophin protein to a level of*30% of wild-type
cells. Viral transduction of DMD hiPSC-cardiomyocytes led
to expression of a dystrophin minigene at the RNA and
protein level to up to 90% of normal dystrophin levels.
Therefore, the hiPSC-cardiomyocyte model can be used to
evaluate the efficacy of novel therapeutics for DMD.
Materials and Methods
Production, maintenance, and differentiation
of hPSC lines
Following informed consent under regulation of local ethics
committee approval 08/H0906/28, human fibroblasts were
prepared from 4mm skin punch biopsies [14]. Fibroblast out-
growths were stored in the BioBank at the MRC centre for
Neuromuscular Diseases in Newcastle. Induction of plur-
ipotency, and establishment and characterization of the hiPSC
lines was using the methods within references [15,16]. Culture
of hESC (HUES7) and hiPSC lines (DMD 4, 7, 11, 15, 16, 19, 21,
and a control hiPSC line, HF-hiPSC [14]) was on Matrigel, in
mouse embryonic fibroblast-conditioned medium [17,18]. Ex-
periments were carried out on hiPSC that were between pas-
sage 15 and 30. Differentiation into cardiomyocytes was by
forced aggregation cells to form embryoid bodies (EBs) [17,18].
Culture of human primary myoblasts
and differentiation into myotubes
Human myoblast cultures were derived from muscle bi-
opsy samples and were obtained from the BioBank. These
cells were cultured in skeletal muscle cell growth medium,
SMGM (Promocell), supplemented with 10% foetal calf se-
rum (Gibco), 4.5mM GlutaMAX (Invitrogen), and 50mg/
mL Gentamicin (Gibco). Cells were maintained at subcon-
fluence over 2–5 passages. For differentiation, myoblasts
were seeded into six well plates according to their growth
rate and allowed to reach 70% confluence over 2–3 days. At
this point, medium was changed to myoblast differentiation
medium, containing high glucose DMEM (Gibco) supple-
mented with 5% heat-inactivated horse serum (Sigma-
Aldrich). After 4–10 days the morphology of the cells changes
and cells fuse to form myotubes.
Immunocytochemistry analysis of DMD
hiPSC-cardiomyocytes
Beating clusters of cardiomyocytes were dissociated into
single cells using a three step method [17]. For cardiac a-actinin
staining, cells were washed with phosphate-buffered saline
(PBS) then fixed in 4%w/v paraformaldehyde and stained [14].
For detection of dystrophin, cells were washed with PBS and
fixed in ice-cold 100% methanol for 1min. Cells were then
washedwithPBS,permeabilizedandstainedfollowingthesame
method as above. The antibodies used for detection of dystro-
phin were Dys-C (C-terminus, Novocastra 1:10), Dys-Rod (rod
domain, Novocastra 1:10), Dys-N (N-terminus, Novocastra
1:10), and MANDYS1 (recognizes epitope in exon 31–32 of
dystrophin; kindgift fromGlennMorris, 1:10). The antibody for
d-sarcoglycan was purchased from Novacastra and used at a
dilution of 1:10. Detection was with a goat anti-mouse Cy3 sec-
ondary antibody (Vector Labs 1:500).Cellswere counterstained
witharabbitanti-cardiac troponinIantibody(Abcam1:200)and
detected with a goat anti-rabbit AlexaFluor 488-conjgated sec-
ondary antibody (Molecular Probes 1:1000). Protein expression
by immunofluorescencewasquantifiedusingVolocitysoftware
(version 5.2.0.0; PerkinElmer) to determine mean fluorescence
intensity of each cell. For flow cytometry, dissociated cells were
fixed with 4% paraformaldehyde, permeabilized with 0.1%
Triton-X100, and then incubated with anti-cardiac troponin I
(1:250) for1 hat roomtemperature.Thesecondaryantibodywas
Alexfluor-488 (1:250; Vector Labs), with staining for 1 h at room
temperature. Cells were then washed in PBS two times before
analyzing using the Beckman Coulter FC500 flow cytometer
with FlowJo software (Treestar).
TaqMan quantitative real-time PCR
TaqMan quantitative PCR was carried out using Applied
Biosystems Assay on Demand primers/probe sets to differ-
ent isoforms of the DMD gene. DMD hiPSCs were differen-
tiated as EBs for 30 days and RNA was collected for analysis.
Differentiated DMD hiPSCs were compared to the
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differentiated control hiPSCs. Expression of the assays de-
tecting all isoforms (Hs00758087_m1), exons 47–48
(Hs01049444_m1), or Dp427m specific (Hs01049418_m1)
mRNA, was quantified using GAPDH as an internal control
(Hs99999905_m1). Assays were carried out using Applied
Biosystems 7500 Fast Real-time PCR System and software.
Electrophysiology analysis by patch clamp
and microelectrode array
For electrophysiological extracellular field potential mea-
surements [14,17], beating clusters were directly seeded onto
Matrigel-coated microelectrode arrays (Scientifica). For phar-
macological analysis, a 5min basal reading was recorded, fol-
lowed by 5min intervals with increasing doses of isoprenaline,
from 1–1000nM. After the final dose, beating clusters were wa-
shed inmediumandallowed to recover for 20min, before taking
a final ‘‘washout’’ reading. For single cell electrophysiology,
whole-cell patch clamp was carried out on dissociated cells, an-
alyzed innormal current-clampmode [14].All electrophysiology
data were analyzed in Axon pClamp 9.0 software.
Exon skipping in DMD hiPSC-cardiomyocytes
and myotubes
For exon-skipping experiments, myotubes, beating clus-
ters or dissociated cardiomyocytes were seeded onto 35mm
MatTek dishes with glass coverslip inserts (MatTek) and
allowed to recover for 3–6 days. Cells were transfected with
polyethylenimine (PEI) (ExGen500; MBI Fermentas) in Opti-
MEM reduced serum medium (Invitrogen) for 3 h, according
to the manufacturer’s instructions. For these experiments
3.5 mL PEI was used per mg anti-sense oligonucleotide (AON)
[11]. For disaggregated cardiomyocytes, a concentration of
100 nM was used, whereas for beating clusters and myotubes
250 nM was used. Cells were transfected with a nontargeting
or AON targeted to skip exon 51(h51AON). Exon skipping
was analyzed by PCR using primers flanking the skipped
area, from exon 43 to exon 54 (forward: 5¢-gctcaggtcg gatt-
gacatt-3¢; reverse: 5¢-tccttagctt ccagccattg-3¢) or by protein
analysis of MANDYS1 expression in hPSC-cardiomyocytes
by immunofluorescence (cardiomyocytes were identified by
reactivity with anti-cardiac troponin I antibodies).
Lentiviral production and transduction
A 4.5 kb dystrophin minigene was cloned into a second
generation pSIN-IRES-blastocidin lentiviral vector. Virus
was produced in the BL15 packaging cells, which have been
engineered from HES293T line and allow purification of vi-
rus using conjugation with streptavidin paramagnetic beads.
A full protocol can be found in reference [19].
Statistics
Statistics were performed using Prism Software (version
5.0 GraphPad).
Results
DMD patient selection
To address the need for an in vitro test-bed in human cells,
we sought to produce hiPSC-cardiomyocytes from patients
with different mutations in the DMD gene. We first
performed isoform-specific reverse transcriptase–PCRs to
identify the expression profile of dystrophin during differ-
entiation of hPSCs to cardiomyocytes. Of the 18 potential
isoforms produced via alternative splicing of transcripts
produced from seven different promoters (Genbank Gene ID
1756; ncbi.nlm.nih.gov/gene/1756), only the short Dp71b
isoform was expressed in undifferentiated cells (Fig. 1A).
Differentiation to cardiomyocytes activated additional ex-
pression of the Dp427m muscle-specific long isoform and the
intermediate Dp140 isoform (Fig. 1A). Therefore, we identi-
fied seven patients who had mutations (i) in the 5¢ end of the
gene, which disrupts only the Dp427m isoform (region 1;
patients DMD11 and DMD 19), (ii) in the middle of the gene,
which disrupts Dp427m and Dp140 (region 2; DMD4,
DMD7, DMD 11, and DMD15), or (iii) in the 3¢ end dis-
rupting all three isoforms (region 3; DMD16) (Fig. 1B, C).
Genotyping confirmed the presence of these mutations. Data
were corroborated by histological and molecular analysis of
muscle biopsies, and by clinical examination (Fig. 1D).
hiPSC production from DMD skin biopsies
Processing and culture of patient skin biopsies produced
outgrowths that were transduced with four reprogramming
factors [19,20], OCT4, SOX2, NANOG, and LIN28, which led
to production of hiPSC over the next 3–4 weeks. hiPSC lines
were established and characterization showed they con-
formed to accepted criteria [21] (Supplementary Fig. S1;
Supplementary Data are available online at www.liebertpub
.com/scd), including morphology, growth kinetics, karyo-
type (passage 15 and 25), immunostaining, and flow
cytometry (positive for OCT4, SOX2, LIN28, NANOG, TRA-
1-81, SSEA4, KLF4, DNMT3B, and CMYC; negative for
SSEA1), and differentiation both in vitro and in vivo to form
representatives of the three germ layers. Notably, formation
of EBs to prime in vitro differentiation was poor when the
hiPSC lines were of passage 10 or less. However, after pas-
sage 15, differentiation was similar to a passage-matched
genetically normal hESC line, HUES7 (data not shown). This
observation is consistent with microarray data that show
gene expression profiles of hiPSCs become more similar to
hESCs relative to increasing passage level [22]. Thus, all
hiPSC and hESC lines in this study were used between
passage 15 and 30.
DMD hiPSC-cardiomyocytes are functional
Production of spontaneously beating cardiomyocytes oc-
curred from day 10 of differentiation of hiPSCs and there
was no apparent difference in efficiency between the lines
(data not shown). For all analyses, areas of beating cells were
mechanically isolated to provide cardiomyocytes that could
be reseeded as intact clusters or as single dissociated cells.
This simple enrichment strategy produced cultures for anal-
ysis in which cardiomyocyte purity was approximately 85%,
as determined by flow cytometry of cells stained with cardiac
troponin I (Fig. 2A). The remaining cells were fibroblasts
on account of their reactivity with the fibroblast-specific
marker, P4HB (prolyl 4-hydroxylase, beta polypeptide; data
not shown). hPSC-cardiomyocytes were charactersized by
immunostaining with a-actinin, which showed sarcomeric
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FIG. 1. Selection of patients har-
boring DMD mutations. In (A), RT-
PCR analysis indicated isoform
Dp71b was expressed in undiffer-
entiated human pluripotent stem
cells (hPSCs) (day 0, d0), while
three isoforms were expressed in
cells differentiating (d2-d18) to-
ward cardiomyocytes (CM). (B)
shows a schematic of the DMD
gene with structures of the ex-
pressed isoforms and (C) provides
mutation and patient details. (Di)
provides representative histopa-
thology and immunostaining of a
skeletal muscle biopsy shown for
donor DMD11 and DMD19, while
(Dii) shows western blot analysis.
RT, reverse transcriptase. Color
images available online at www
.liebertpub.com/scd
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FIG. 2. Cardiac differentiation of Duchenne muscular dystrophy (DMD) human induced pluripotent stem cells (hiPSC)
lines. (A) Mechanically dissecting beating areas from differentiated embryoid bodies resulted in cardiomyocyte preparations
in which over 80% of the cells were positive for cardiac troponin I by flow cytometry. (B) Beating clusters were dissociated to
yield single cardiomyocytes that were fixed and stained with cardiac a-actinin. Inset images show sarcomeric striations.
Analysis of single cells by whole-cell patch clamp (Ci) shows presence of ventricular-, atrial-, and pacemaker-like cells (Cii)
and by multielectrode array (Di) shows field potential trances (Dii) and pharmacological responses to the b-adrenoceptor
agonist, isoprenaline (Diii, y axis is beat rate relative to untreated basal samples). Images and representative responses in (C)
and (D) are for DMD hiPSC 16 except for Diii, which shows DMD hiPSC16 cardiomyocytes versus hESC (HUES7) cardi-
omyocytes. At this basic level of analysis, similar responses were seen for the other hiPSC lines. w/o=washout. Scale bars
represent 20 mm in (B) and (C), and 100 mm in (D). Color images available online at www.liebertpub.com/scd
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striations typical of these cells (Fig. 2B). Whole cell patch
clamp electrophysiology indicated presence of atrial-, ven-
tricular-, and pacemaker-like cardiac subtypes (Fig. 2C),
while extracellular field potentials could be detected by
multielectrode array analysis (Fig. 2D). Stimulation with es-
calating doses (1–1000 nM) of the b-adrenoceptor agonist,
isoprenaline, led to increased beat rates (to 135%– 14% at
1mM) similar to those seen for HUES7 cells (P= 0.38; t-test)
and the chronotropic effect was reversed by drug washout.
Therefore, the DMD-hiPSC lines could be differentiated into
functional cardiomyocytes.
Mutation profile is retained during differentiation
of DMD hiPSCs
Since differentiation of the lines proved to be similar, we
elected to use lines DMD hiPSC4 (deletion exons 48–50),
DMD hiPSC7 (deletion exons 47–50), DMD hiPSC16 (point
mutation in exon 70: c.3217G >T causing p.Trp1029· ), and
DMD19 (deletion of TG from exon 35) in subsequent studies.
Lines 4 and 7 would be suitable for testing exon 51 skipping,
while lines 16 and 19 would allow testing overexpression of
a mini dystrophin construct.
To confirm the dystrophic gene expression status of these
hiPSC lines, each was differentiated and examined by
quantitative real-time PCR (Fig. 3). Assay 1, with primers
located in regions 1 (exons 1–2, detects Dp427 muscle-spe-
cific isoform), showed significant reduction in expression in
each of the hiPSC lines (Fig. 3B; P = < 0.01 to < 0.001). Assay
2 (Region 2; exons 47–48, Dp427m and Dp140) detected
significant reductions in gene expression for hiPSC lines,
DMD4, DMD7, and DMD16 (P = < 0.01 to < 0.001). However,
with the region 3 assay (exons 75–76, detects Dp427m,
Dp140, and Dp71b), only DMD hiPSC16 cells had signifi-
cantly reduced transcript levels (P = 0.022), consistent with
the exon 70 point mutation affecting all three isoforms
(Dp427m, Dp140, and Dp71b).
These data were also corroborated at the protein level,
where an antibody to region 3 (C-terminus) detected ex-
pression in cardiomyocytes from DMD hiPSC4, DMD
hiPSC7, and DMD hiPSC19 but not DMD hiPSC16 (Fig. 4).
Dystrophin expression could not be detected in DMD
hiPSC4, DMD hiPSC7, and DMD hiPSC16 using antibodies
to region 2 (rod domain), while expression was not detected
in any of the lines when probing region 1 (N-terminus). In all
cases, staining with these antibodies showed dystrophin
expression in normal myotubes or hPSC-cardiomyocytes in
which DMD mutations were absent (Fig. 4). These data in-
dicated that the gene expression profile of dystrophin in cells
differentiated from the hiPSC lines matched the mutation
status.
Genetic therapies facilitate dystrophin expression
in DMD hiPSC-cardiomyocytes
Over 70% of DMD cases are caused by deletions of one or
several exons of the dystrophin gene usually resulting in loss
of the reading frame, and absence of dystrophin protein [23].
In particular, the central rod domain flanking exon 50 is a hot
spot for deletions. This is typified by DMD hiPSC4 (exons
48–50) and DMD hiPSC7 (exons 47–50), which were selected
as representative examples for evaluating exon-skipping
drugs, particularly those for exon 51. Clinical trials are on-
going with both 2OMePS and PMOs (2¢-O-methyl phos-
phorothioate and phosphorodiamidate morpholino oligos).
Here, we employed 2OMePS, which are developed furthest.
FIG. 3. Gene expression analysis of DMD hiPSCs. (A) The schematic shows locations of TaqMan quantitative PCR assays in
the DMD gene, with assay 1 primers detecting exons 1–2 of the Dp427m isoform, assay 2 primers detecting exons 47–48, and
assay 3 primers detecting exons 75–76. (B) Assays were used to analyze the expression of hiPSC lines at day 30 of cardio-
myocyte differentiation and are normalized against GAPDH. RQ, relative quantification; for each hiPSC line and each assay,
expression level of control samples normalized to a value of 1 and data are plotted relative to this value. Data are mean – SEM
of three independent differentiation experiments and significance versus control is *P < 0.05, **P < 0.01, and ***P < 0.001,
analyzed by one-way ANOVA and Dunnett’s post-tests.
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These drugs have been shown to function in patients and can
be transfected at higher efficiencies than PMOs into myo-
blasts in vitro to induce exon skipping (Supplementary Fig.
S2 and ref [24]).
Our initial attempts to transfect hiPSC-cardiomyocytes
with fluorescently-tagged AONs were unsuccessful due to
high toxicity and loss of cell viability. However, by reducing
the concentration of the cationic lipid transfection reagent
and optimizing timing and lipid:AON ratios, delivery to 90%
of the hiPSC-cardiomyocytes was achieved (Supplementary
Fig. S2). Transfection of DMD hiPSC-cardiomyocytes with
exon 51 AONs caused exon skipping, and sequencing
showed in-frame transcripts of exon 47–52 and 46–52 in lines
4 and 7, respectively (Fig. 5A, B). By day 3 after AON
transfection, immunostaining showed dystrophin protein
was approaching 30% of control cardiomyocytes (Fig. 5A–C),
which corresponds to the level of rescue required for thera-
peutic benefit [25].
Since mini dystrophin constructs are being evaluated as
potential therapies in the skeletal muscle of DMD patients,
we sought to evaluate whether a 4.5 kb construct could
restore expression in DMD hiPSC cardiomyocytes. We se-
lected DMD hiPSC16 that harbors a stop mutation in exon
70, which is located outside the redundant central rod do-
main and hence exon skipping is unlikely to render a
functional protein. This mutation disrupts all three dys-
trophin isoforms expressed in cardiomyocytes derived from
hPSCs. In addition, we tested the minigene in DMD
hiPSC19. The dinucleotide deletion in this line lies in region
1 (exon 35) and hence only disrupts the longest isoforms
expressed in hPSC-derived cardiomyocytes. It also is out-
side of the exon 45–55 mutation hotspot region that is an
appealing target for exon skipping. Lentiviral delivery of a
4.5 kb dystrophin minigene to cardiomyocytes derived
from a healthy control DMD hPSC and from DMD hiPSC16
resulted in strong reverse transcriptase (RT)-PCR signals
FIG. 4. Protein expression
in DMD hiPSCs. A schematic
shows location of antibodies
that detect N-terminus (Dys-
N), rod domain (Dys-Rod),
and C-terminus (Dys-C) of
dystrophin (A). In (B) these
antibodies and a d-sarcogly-
can control antibody were
detected using a Cy3-conju-
gate (red, main images) and
cells were counterstained
with a cardiac Troponin I
AlexaFluor 488 antibody
(green, merge shown in in-
sets). Controls included ge-
netically normal myotubes
from skeletal muscle and
cardiomyocytes derived from
HUES7 hESC. Scale bars rep-
resent 20mm. Color images
available online at www.lie
bertpub.com/scd
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after minigene-specific RT-PCR primers (Fig. 6B). At the
protein level, cardiomyocytes were co-stained with cardiac
troponin I and C-terminal dystrophin antibodies. This
showed lentiviral transduction led to expression of the
minigene in cardiomyocytes derived from DMD hiPSC16
and DMD hiPSC 19 at levels of 66% and 91%, respectively,
of healthy, nontransduced control hPSC-cardiomyocytes
(Fig. 6C, D). These levels were achieved because the car-
diomyocyte transduction efficiency was *55% and these
cells expressed dystrophin at up to 1.6-fold relative to
healthy control cardiomyocytes (data not shown).
Thus, the DMD hiPSC model was successfully used to
determine whether gene transfer and exon skipping strate-
gies could restore dystrophin expression in cardiomyocytes,
thereby providing a useful in vitro test platform.
Discussion
Our work shows that biopsies from DMD patients can be
reprogrammed to hiPSC and differentiated into functional car-
diomyocytes,whichcanbeusedasamodelhumansystemto test
whether genetic-based therapeutics can restore dystrophin
FIG. 5. Exon skipping restores dystrophin expression in DMD hiPSC. (A) DMD hiPSC4 cardiomyocytes (exon 48–50
deletion) or (B) DMD hiPSC7 cardiomyocytes (exon 47–50 deletion) were transfected with nontargeting (NT) 2OMePS AONs
or thosedirected towardexon51.RT-PCRwithprimers residing inexons43and54producedabandof 1229 bp forDMD4(splice 47
to51) andof1079 bp forDMD7(splice46 to51).Whenskippingoccurs, these sizes reduce to996 bp forDMD4(splice47 to52) and to
846bp for DMD7 (splice 46 and 52). PCR bandswere excised and sequenced to confirm splice junctions. Datawere corroborated at
theprotein levelusing theMANDYS1antibodywithaCy3-conjugte (red,main images) andcounterstainedwitha cardiacTroponin
I AlexaFluor 488 antibody (green, merge shown in insets). Scale bars represent 20mm. (C) Image quantification in cTnI-expressing
cells showed significant restoration of dystrophin expression. In DMD hiPSC cardiomyocytes treated with nontargeting AONs,
levels of dystrophin expression were undetectable and scored as zero. In contrast, DMD hiPSC cardiomyocytes treated with the
exon 51AONs showed restoration of dystrophin expression to nearly 30% of the genetically normal control (CONT; referenced as
100% expression level, which was determined from HUES7 hESC-derived cardiomyocytes). Data are mean– SEM (** represents
P< 0.01, students t-test). Color images available online at www.liebertpub.com/scd
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FIG. 6. Dystrophin minigene expression in DMD hiPSC. (A) Shows a schematic of the 4.5 kb dystrophin minigene cloned
into second generation recombinant lentivirus. Cardiomyocytes from genetically normal HUES7 hESCs and from the DMD
hiPSCs lines were transduced with the dystrophin minigene. Five days later, RNA (B) and protein (C) analyses were
performed, with quantification restricted to cardiomyocytes expressing cTnI from immunofluorescence images (D). Samples
were without ( - ) or with ( + ) virus transduction at multiplicity of infection of 100. A PCR band of*300 bp is specific to the
dystrophin minigene. Immunofluorescence images show staining with an antibody to the C-terminus (Dys-C; red, main
images) counterstained with a cardiac troponin I antibody (green) and DAPI (blue). ** represents P £ 0.01, t-test. Scale bar
represents 20 mm. Color images available online at www.liebertpub.com/scd
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expression. The ease of transfecting hiPSC cardiomyocytes with
2OMePSAONswill beuseful indefiningwhich target sequences
cause successful exon skipping in the heart, and whether this
differs from cultured skeletal muscle cells. It also allows testing
the ability of different mini- and micro-dystrophin constructs to
produce protein in heart cells. Here, we tested delivery of a
dystrophinminigene using recombinant lentivirus, although the
system could be used to evaluate any viral or nonviral method.
Clinical trials (see clinicaltrials.gov) are currently being initiated
orareunderwayusing lentiviral-mediateddeliveryof transgenes
for esophageal cancer, skin disorders (e.g., Netherton Syn-
drome), and age-related macular degeneration, thereby provid-
ing therapeutic premise for the work presented in this article.
Interestingly, cardiac problems are frequent in Becker patients
and sometimes are the predominant symptom [26]. Thus, it is
possible that while Becker-like dystrophins can improve skeletal
muscle quality and function, they are less functional in the heart.
Testing delivery in human cardiomyocytes and myoblasts in
parallel will be important because cardiomyocytes have higher
levels of RNA and higher RNA processivity, coupled with
turnover of RNA. Thus, therapeutics discounted for low efficacy
in myoblasts may be useful in cardiomyocytes.
Defining suitable target sequences will also allow their
incorporation into other oligonucleotide-based strategies that
are more difficult or expensive to test in culture. For exam-
ple, it is challenging to deliver PMOs to cells in culture on
account of the neutral charge of these skipping drugs [24].
The hiPSC-cardiomyocyte could also be used to test delivery
and efficacy of pPMOs. Delivery of AONs expressed from
viral vectors (e.g., adeno-associated virus [27] or lentivirus
[28]) has been achieved but this strategy is costly and it is
time consuming to screen large numbers of target sequences.
Similarly, the system could be used to test the efficiency of
uptake of new AON chemistries or methods of uptake, such
as the use of cell-penetrating peptides [29,30]. It is notable
that even when methods deliver limited quantities of skip-
ping agents, dystrophin expression can be restored. For ex-
ample, it has been shown that low skipping levels restored
dystrophin to *75% of normal in cultured muscle cells [31].
Another advantage of the in vitro cardiomyocyte platform
is that it will enable drug-induced cardiotoxic effects to be
investigated. Cardiomyocytes from hESC and hiPSC have
been validated in detection of drug-induced electrical dis-
turbances, structural changes (e.g., hypertrophy), and re-
duced survival [14,32,33], providing opportunities to use
these cells in toxicity testing of genetic-based therapies. The
next stage will be to refine the DMD hiPSC-cardiomyocyte
model so that in vitro function can be correlated with ge-
notype and clinical pathophysiology. This has been achieved
for conditions such as long QT syndrome [14], where elec-
trical abnormalities in the patient’s heart are reflected in the
derived hiPSC-cardiomyocytes in culture. Such systems are
now being used as a platform to test efficacy of experimental
therapeutics. Making similar correlations for more subtle
genotype–phenotype correlations that affect cell structure or
integrity will be more challenging but also holds consider-
able reward once achieved.
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